vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
CHIMERA INVESTMENT CORP is the larger business by last-quarter revenue ($66.2M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs -83.0%, a 125.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 0.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CIM vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $57.3M |
| Net Profit | $28.3M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 42.6% | -82.2% |
| Net Margin | 42.8% | -83.0% |
| Revenue YoY | 0.5% | 36.9% |
| Net Profit YoY | 119.3% | -9.6% |
| EPS (diluted) | $0.05 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $57.3M | ||
| Q3 25 | $65.0M | $51.3M | ||
| Q2 25 | $66.0M | $48.5M | ||
| Q1 25 | $69.2M | $32.7M | ||
| Q4 24 | $65.8M | $41.8M | ||
| Q3 24 | $66.5M | $33.3M | ||
| Q2 24 | $67.3M | $29.1M | ||
| Q1 24 | $65.1M | $26.0M |
| Q4 25 | $28.3M | $-47.5M | ||
| Q3 25 | $-580.0K | $-52.9M | ||
| Q2 25 | $35.5M | $-46.6M | ||
| Q1 25 | $167.3M | $-49.5M | ||
| Q4 24 | $-146.5M | $-43.3M | ||
| Q3 24 | $136.5M | $-43.6M | ||
| Q2 24 | $56.7M | $-32.3M | ||
| Q1 24 | $129.5M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 42.6% | -82.2% | ||
| Q3 25 | -0.5% | -102.6% | ||
| Q2 25 | 54.3% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | -222.6% | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | 84.2% | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | 42.8% | -83.0% | ||
| Q3 25 | -0.9% | -103.1% | ||
| Q2 25 | 53.7% | -96.1% | ||
| Q1 25 | 241.7% | -151.4% | ||
| Q4 24 | -222.6% | -103.6% | ||
| Q3 24 | 205.4% | -131.2% | ||
| Q2 24 | 84.2% | -110.9% | ||
| Q1 24 | 198.8% | -544.4% |
| Q4 25 | $0.05 | $-0.73 | ||
| Q3 25 | $-0.27 | $-0.82 | ||
| Q2 25 | $0.17 | $-0.75 | ||
| Q1 25 | $1.77 | $-0.81 | ||
| Q4 24 | $-2.06 | $-0.71 | ||
| Q3 24 | $1.39 | $-0.73 | ||
| Q2 24 | $0.41 | $-0.55 | ||
| Q1 24 | $1.36 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $388.9M |
| Total DebtLower is stronger | $251.5M | — |
| Stockholders' EquityBook value | $2.6B | $139.1M |
| Total Assets | $15.8B | $480.2M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $388.9M | ||
| Q3 25 | $491.5M | $416.1M | ||
| Q2 25 | $250.2M | $291.0M | ||
| Q1 25 | $253.3M | $314.5M | ||
| Q4 24 | $84.0M | $320.6M | ||
| Q3 24 | $97.3M | $298.4M | ||
| Q2 24 | $162.3M | $319.1M | ||
| Q1 24 | $169.0M | $201.2M |
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $139.1M | ||
| Q3 25 | $2.6B | $148.8M | ||
| Q2 25 | $2.6B | $-11.9M | ||
| Q1 25 | $2.6B | $18.9M | ||
| Q4 24 | $2.5B | $21.7M | ||
| Q3 24 | $2.7B | $11.2M | ||
| Q2 24 | $2.6B | $39.3M | ||
| Q1 24 | $2.6B | $61.6M |
| Q4 25 | $15.8B | $480.2M | ||
| Q3 25 | $15.1B | $506.9M | ||
| Q2 25 | $14.9B | $372.7M | ||
| Q1 25 | $13.2B | $386.7M | ||
| Q4 24 | $13.1B | $392.3M | ||
| Q3 24 | $13.7B | $363.6M | ||
| Q2 24 | $13.1B | $381.8M | ||
| Q1 24 | $12.5B | $258.7M |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -8.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $-25.4M | ||
| Q3 25 | $-137.5M | $-26.6M | ||
| Q2 25 | $-7.4M | $-23.3M | ||
| Q1 25 | $48.8M | $-40.4M | ||
| Q4 24 | $205.7M | $-18.8M | ||
| Q3 24 | $41.4M | $-25.2M | ||
| Q2 24 | $69.0M | $-29.1M | ||
| Q1 24 | $57.3M | $-40.7M |
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
